1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Chronic Disease Market Trends
  5. > Radiculopathy Global Clinical Trials Review, H1, 2016

Radiculopathy Global Clinical Trials Review, H1, 2016

  • March 2016
  • -
  • Global Data
  • -
  • 56 pages

Radiculopathy Global Clinical Trials Review, H1, 2016

Summary

GlobalData's clinical trial report, “Radiculopathy Global Clinical Trials Review, H1, 2016" provides an overview of Radiculopathy clinical trials scenario. This report provides top line data relating to the clinical trials on Radiculopathy. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table Of Contents

Radiculopathy Global Clinical Trials Review, H1, 2016
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Report Guidance 5
Clinical Trials by Region 6
Clinical Trials and Average Enrollment by Country 7
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Countries Contributing to Clinical Trials in Middle East and Africa 13
Clinical Trials by G7 Countries: Proportion of Radiculopathy to Central Nervous System Clinical Trials 14
Clinical Trials by Phase in G7 Countries 15
Clinical Trials in G7 Countries by Trial Status 16
Clinical Trials by E7 Countries: Proportion of Radiculopathy to Central Nervous System Clinical Trials 17
Clinical Trials by Phase in E7 Countries 18
Clinical Trials in E7 Countries by Trial Status 19
Clinical Trials by Phase 20
In Progress Trials by Phase 21
Clinical Trials by Trial Status 22
Clinical Trials by End Point Status 23
Subjects Recruited Over a Period of Time 24
Clinical Trials by Sponsor Type 25
Prominent Sponsors 26
Top Companies Participating in Radiculopathy Therapeutics Clinical Trials 28
Prominent Drugs 30
Clinical Trial Profile Snapshots 31
Appendix 53
Abbreviations 53
Definitions 53
Research Methodology 54
Secondary Research 54
About GlobalData 55
Contact Us 55
Disclaimer 55
Source 56

List of Tables
Radiculopathy Therapeutics, Global, Clinical Trials by Region, 2016* 6
Radiculopathy Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 8
Radiculopathy Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 9
Radiculopathy Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2016* 10
Radiculopathy Therapeutics Clinical Trials, Europe, Top Five Countries, 2016* 11
Radiculopathy Therapeutics Clinical Trials, North America, Top Countries, 2016* 12
Radiculopathy Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2016* 13
Proportion of Radiculopathy to Central Nervous System Clinical Trials, G7 Countries (%), 2016* 14
Radiculopathy Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 15
Radiculopathy Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 16
Proportion of Radiculopathy to Central Nervous System Clinical Trials, E7 Countries (%), 2016* 17
Radiculopathy Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 18
Radiculopathy Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 19
Radiculopathy Therapeutics, Global, Clinical Trials by Phase, 2016* 20
Radiculopathy Therapeutics, Global, Clinical Trials In Progress by Phase 2016* 21
Radiculopathy Therapeutics, Global, Clinical Trials by Trial Status, 2016* 22
Radiculopathy Therapeutics Clinical Trials, Global, by End Point Status, 2016* 23
Radiculopathy Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 24
Radiculopathy Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2016* 25
Radiculopathy Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 27
Radiculopathy Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 29
Radiculopathy Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 30

List of Figures
Radiculopathy Therapeutics, Global, Clinical Trials by Region (%), 2016* 6
Radiculopathy Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 7
Radiculopathy Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 9
Radiculopathy Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2016* 10
Radiculopathy Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2016* 11
Radiculopathy Therapeutics Clinical Trials, North America, Top Countries (%), 2016* 12
Proportion of Radiculopathy to Central Nervous System Clinical Trials, G7 Countries (%), 2016* 14
Radiculopathy Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 15
Radiculopathy Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 16
Proportion of Radiculopathy to Central Nervous System Clinical Trials, E7 Countries (%), 2016* 17
Radiculopathy Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 18
Radiculopathy Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 19
Radiculopathy Therapeutics, Global, Clinical Trials by Phase (%), 2016* 20
Radiculopathy Therapeutics, Global, Clinical Trials In Progress by Phase, 2016* 21
Radiculopathy Therapeutics, Global, Clinical Trials by Trial Status, 2016* 22
Radiculopathy Therapeutics Clinical Trials, Global, by End Point Status, 2016* 23
Radiculopathy Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 24
Radiculopathy Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2016* 25
Radiculopathy Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 26
Radiculopathy Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 28
Radiculopathy Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 30
GlobalData Methodology 54

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Systemic Lupus Erythematosus Market: By Therapies (Antimalarial Drugs, Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Corticosteroids Cytotoxic & Immunosuppressive Drugs, Biologics, Small Molecules) & By Region (Asia-Pacific, Others)-Forecast (2016-2021)

Systemic Lupus Erythematosus Market: By Therapies (Antimalarial Drugs, Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Corticosteroids Cytotoxic & Immunosuppressive Drugs, Biologics, Small Molecules) & By Region (Asia-Pacific, Others)-Forecast (2016-2021)

  • $ 5250
  • Industry report
  • September 2016
  • by Industry ARC

Systemic lupus erythematosus, also commonly known as lupus, is an autoimmune disease which results in inflammation of tissues in the body with common symptoms like fever, fatigue, skin rashes, malaise, ...

Epiomic Epidemiology Series: Osteoarthritis Forecast in 9 Major Markets 2016-2026

Epiomic Epidemiology Series: Osteoarthritis Forecast in 9 Major Markets 2016-2026

  • $ 5112
  • Industry report
  • October 2016
  • by Black Swan Analysis Ltd132

Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Osteoarthritis in 9 Major Markets Osteoarthritis (OA), also known as degenerative joint disease / degenerative arthritis, is an inflammation ...

Global Osteoporosis Drugs Market Size, Share, Development, Growth and Demand Forecast to 2022- Industry Insights by Drug Class

Global Osteoporosis Drugs Market Size, Share, Development, Growth and Demand Forecast to 2022- Industry Insights by Drug Class

  • $ 5100
  • Industry report
  • November 2016
  • by P&S Market Research

The global osteoporosis drugs market was worth $8,835.4 million in 2015 and it is expected to grow at a CAGR of 3.8% during 2016-2022. Among the various drug classes, the rank ligand inhibitors segment ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.